Source: Annual Congress 2013 –Recent developments in pneumonia
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. Bledel, A. Raimondi, A. Sosa, S. Sarquis, C. Irrazabal, A. Capdevila, C. Vay, A. Famiglietti, C. M. Luna (Buenos Aires, Argentina). Ventilator-associated pneumonia (VAP) pathogenic microorganisms eradication and persistence during antimicrobial therapy. Eur Respir J 2013; 42: Suppl. 57, 5048

Member's Comments

No comment yet.

Related content which might interest you: Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Implications of identifying the pathogen in ventilator-associated pneumonia (VAP) Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006 Effectiveness of immune stimulatory therapy in patient with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Multidrug resistant acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014 Prevention of nosocomial infections in acute respiratory failure patients Source: Eur Respir J 2003; 22: 72S-76S Year: 2003 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Appropriateness and delay to initiate therapy in ventilator-associated pneumonia Source: Eur Respir J 2006; 27: 158-164 Year: 2006 Impact of candida spp. colonization of respiratory tract in patients with intensive care unit-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Respiratory infections in the immunocompetent host: from asthma exacerbations to hospital-acquired pneumonia Source: Annual Congress 2007 - Infections year in review Year: 2007 Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome Source: Eur Respir J 2002; 20: 1483-1489 Year: 2002 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Effect of de-escalation antibiotic therapy on hospital-acquired, ventilator associated, and healthcare-associated pneumonia: A systematic review and meta-analysis Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016 Bundles for the prevention of ventilator-associated pneumonia in a Brazilian hospital Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients Source: Eur Respir J 2016; 47: 1060-1061 Year: 2016 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011